FY2030 Earnings Estimate for TARA Issued By HC Wainwright

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Protara Therapeutics in a report issued on Wednesday, March 11th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.09) for the year. HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

TARA has been the topic of a number of other research reports. Piper Sandler initiated coverage on shares of Protara Therapeutics in a report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 price target on the stock. JPMorgan Chase & Co. started coverage on Protara Therapeutics in a research note on Wednesday, March 4th. They set an “overweight” rating and a $27.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Protara Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $5.60 on Thursday. The firm has a market cap of $289.13 million, a P/E ratio of -4.24 and a beta of 1.40. Protara Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.82. The firm has a 50-day simple moving average of $6.10 and a two-hundred day simple moving average of $5.35.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03).

Institutional Investors Weigh In On Protara Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TARA. Rhumbline Advisers grew its position in Protara Therapeutics by 8.2% in the 3rd quarter. Rhumbline Advisers now owns 34,137 shares of the company’s stock worth $148,000 after purchasing an additional 2,596 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Protara Therapeutics by 26.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,736 shares of the company’s stock worth $111,000 after acquiring an additional 4,383 shares during the period. Two Sigma Investments LP grew its holdings in shares of Protara Therapeutics by 35.8% in the third quarter. Two Sigma Investments LP now owns 19,558 shares of the company’s stock worth $85,000 after acquiring an additional 5,154 shares during the period. Charles Schwab Investment Management Inc. increased its position in Protara Therapeutics by 7.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 102,499 shares of the company’s stock valued at $546,000 after acquiring an additional 6,725 shares during the last quarter. Finally, Quadrature Capital Ltd lifted its holdings in Protara Therapeutics by 39.4% in the fourth quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock valued at $129,000 after acquiring an additional 6,838 shares during the period. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.